Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 328

1.

Longitudinal survey of condom use across a US Navy and Marine Corps shipboard deployment.

Harbertson J, De Vera K, Scott PT, Li Y, Shaffer RA, Michael NL, Hale BR.

BMJ Open. 2019 Jun 22;9(6):e028151. doi: 10.1136/bmjopen-2018-028151.

2.

Effect of HIV infection and antiretroviral therapy on immune cellular functions.

Korencak M, Byrne M, Richter E, Schultz BT, Juszczak P, Ake JA, Ganesan A, Okulicz JF, Robb ML, de Los Reyes B, Winning S, Fandrey J, Burgess TH, Esser S, Michael NL, Agan BK, Streeck H.

JCI Insight. 2019 Jun 20;4(12). pii: 126675. doi: 10.1172/jci.insight.126675. eCollection 2019 Jun 20.

3.

Correction: Trinh, H.V., et al. Humoral Response to the HIV-1 Envelope V2 Region in a Thai Early Acute Infection Cohort. Cells 2019, 8, 365.

Trinh HV, Gohain N, Pham PT, Hamlin C, Song H, Sanders-Buell E, Bose M, Eller LA, Jain S, Uritskiy G, Rao VB, Tovanabutra S, Michael NL, Robb ML, Joyce MG, Rao M.

Cells. 2019 Jun 6;8(6). pii: E554. doi: 10.3390/cells8060554.

4.

The breadth of HIV-1 neutralizing antibodies depends on the conservation of key sites in their epitopes.

Bai H, Li Y, Michael NL, Robb ML, Rolland M.

PLoS Comput Biol. 2019 Jun 6;15(6):e1007056. doi: 10.1371/journal.pcbi.1007056. eCollection 2019 Jun.

5.

HIV-1 genetic diversity and demographic characteristics in Bulgaria.

Billings E, Heipertz RA, Varleva T, Sanders-Buell E, O'Sullivan AM, Bose M, Howell S, Kijak GH, Taskov H, Elenkov I, Nenova M, Popivanova N, Valenzuela AB, Myles O, Bautista CT, Robb ML, Michael NL, Kim JH, Scott PT, Tovanabutra S, Ake JA.

PLoS One. 2019 May 28;14(5):e0217063. doi: 10.1371/journal.pone.0217063. eCollection 2019.

6.

New Subtype B Containing HIV-1 Circulating Recombinant of sub-Saharan Africa Origin in Nigerian Men Who Have Sex With Men.

Billings E, Kijak GH, Sanders-Buell E, Ndembi N, OʼSullivan AM, Adebajo S, Kokogho A, Milazzo M, Lombardi K, Baral S, Nowak R, Ramadhani H, Gramzinski R, Robb ML, Michael NL, Charurat ME, Ake J, Crowell TA, Tovanabutra S; MHRP Viral Sequencing Core and the TRUST/RV368 Study Group.

J Acquir Immune Defic Syndr. 2019 Aug 15;81(5):578-584. doi: 10.1097/QAI.0000000000002076.

PMID:
31107298
7.

Expansion of Stem Cell-Like CD4+ Memory T Cells during Acute HIV-1 Infection Is Linked to Rapid Disease Progression.

Pušnik J, Eller MA, Tassaneetrithep B, Schultz BT, Eller LA, Nitayaphan S, Kosgei J, Maganga L, Kibuuka H, Alter G, Michael NL, Robb ML, Streeck H.

J Virol. 2019 Jun 28;93(14). pii: e00377-19. doi: 10.1128/JVI.00377-19. Print 2019 Jul 15.

PMID:
31043532
8.

Humoral Response to the HIV-1 Envelope V2 Region in a Thai Early Acute Infection Cohort.

Trinh HV, Gohain N, Pham PT, Hamlin C, Song H, Sanders-Buell E, Bose M, Eller LA, Tovanabutra S, Michael NL, Robb ML, Joyce MG, Rao M.

Cells. 2019 Apr 19;8(4). pii: E365. doi: 10.3390/cells8040365.

9.

Cross-Sectional Study of Sexual Behavior, Alcohol Use, and Mental Health Conditions Associated With Sexually Transmitted Infections Among Deploying Shipboard US Military Personnel.

Harbertson J, Scott PT, Lemus H, Michael NL, Hale BR.

Mil Med. 2019 Apr 20. pii: usz070. doi: 10.1093/milmed/usz070. [Epub ahead of print]

PMID:
31004170
10.

Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial.

Crowell TA, Colby DJ, Pinyakorn S, Sacdalan C, Pagliuzza A, Intasan J, Benjapornpong K, Tangnaree K, Chomchey N, Kroon E, de Souza MS, Tovanabutra S, Rolland M, Eller MA, Paquin-Proulx D, Bolton DL, Tokarev A, Thomas R, Takata H, Trautmann L, Krebs SJ, Modjarrad K, McDermott AB, Bailer RT, Doria-Rose N, Patel B, Gorelick RJ, Fullmer BA, Schuetz A, Grandin PV, O'Connell RJ, Ledgerwood JE, Graham BS, Tressler R, Mascola JR, Chomont N, Michael NL, Robb ML, Phanuphak N, Ananworanich J; RV397 Study Group.

Lancet HIV. 2019 May;6(5):e297-e306. doi: 10.1016/S2352-3018(19)30053-0. Epub 2019 Apr 15.

PMID:
31000477
11.

Next-generation sequencing of HIV-1 single genome amplicons.

Kijak GH, Sanders-Buell E, Pham P, Harbolick EA, Oropeza C, O'Sullivan AM, Bose M, Beckett CG, Milazzo M, Robb ML, Peel SA, Scott PT, Michael NL, Armstrong AW, Kim JH, Brett-Major DM, Tovanabutra S.

Biomol Detect Quantif. 2019 Mar 11;17:100080. doi: 10.1016/j.bdq.2019.01.002. eCollection 2019 Mar.

12.

Modeling HIV-1 Latency Using Primary CD4+ T Cells from Virally Suppressed HIV-1-Infected Individuals on Antiretroviral Therapy.

Takata H, Kessing C, Sy A, Lima N, Sciumbata J, Mori L, Jones RB, Chomont N, Michael NL, Valente S, Trautmann L.

J Virol. 2019 May 15;93(11). pii: e02248-18. doi: 10.1128/JVI.02248-18. Print 2019 Jun 1.

PMID:
30918072
13.

Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting.

Julg B, Dee L, Ananworanich J, Barouch DH, Bar K, Caskey M, Colby DJ, Dawson L, Dong KL, Dubé K, Eron J, Frater J, Gandhi RT, Geleziunas R, Goulder P, Hanna GJ, Jefferys R, Johnston R, Kuritzkes D, Li JZ, Likhitwonnawut U, van Lunzen J, Martinez-Picado J, Miller V, Montaner LJ, Nixon DF, Palm D, Pantaleo G, Peay H, Persaud D, Salzwedel J, Salzwedel K, Schacker T, Sheikh V, Søgaard OS, Spudich S, Stephenson K, Sugarman J, Taylor J, Tebas P, Tiemessen CT, Tressler R, Weiss CD, Zheng L, Robb ML, Michael NL, Mellors JW, Deeks SG, Walker BD.

Lancet HIV. 2019 Apr;6(4):e259-e268. doi: 10.1016/S2352-3018(19)30052-9. Epub 2019 Mar 15. Review.

PMID:
30885693
14.

Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual.

Krebs SJ, Kwon YD, Schramm CA, Law WH, Donofrio G, Zhou KH, Gift S, Dussupt V, Georgiev IS, Schätzle S, McDaniel JR, Lai YT, Sastry M, Zhang B, Jarosinski MC, Ransier A, Chenine AL, Asokan M, Bailer RT, Bose M, Cagigi A, Cale EM, Chuang GY, Darko S, Driscoll JI, Druz A, Gorman J, Laboune F, Louder MK, McKee K, Mendez L, Moody MA, O'Sullivan AM, Owen C, Peng D, Rawi R, Sanders-Buell E, Shen CH, Shiakolas AR, Stephens T, Tsybovsky Y, Tucker C, Verardi R, Wang K, Zhou J, Zhou T, Georgiou G, Alam SM, Haynes BF, Rolland M, Matyas GR, Polonis VR, McDermott AB, Douek DC, Shapiro L, Tovanabutra S, Michael NL, Mascola JR, Robb ML, Kwong PD, Doria-Rose NA.

Immunity. 2019 Mar 19;50(3):677-691.e13. doi: 10.1016/j.immuni.2019.02.008. Epub 2019 Mar 12.

PMID:
30876875
15.

Impact of Early Antiretroviral Therapy on Detection of Cell-Associated HIV-1 Nucleic Acid in Blood by the Roche Cobas TaqMan Test.

Jagodzinski LL, Manak MM, Hack HR, Liu Y, Malia JA, Freeman J, Phanuphak N, de Souza M, Kroon ED, Colby DJ, Chomchey N, Lally MA, Michael NL, Ananworanich J, Peel SA; RV254/SEARCH010 Study Team.

J Clin Microbiol. 2019 Apr 26;57(5). pii: e01922-18. doi: 10.1128/JCM.01922-18. Print 2019 May.

16.

Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine.

Fourati S, Ribeiro SP, Blasco Tavares Pereira Lopes F, Talla A, Lefebvre F, Cameron M, Kaewkungwal J, Pitisuttithum P, Nitayaphan S, Rerks-Ngarm S, Kim JH, Thomas R, Gilbert PB, Tomaras GD, Koup RA, Michael NL, McElrath MJ, Gottardo R, Sékaly RP.

Nat Commun. 2019 Feb 20;10(1):863. doi: 10.1038/s41467-019-08854-2.

17.

Time to change the paradigm: limited condom and lubricant use among Nigerian men who have sex with men and transgender women despite availability and counseling.

Crowell TA, Baral SD, Schwartz S, Nowak RG, Kokogho A, Adebajo S, Keshinro B, Makanjuola O, Michael NL, Robb ML, Charurat ME, Ake JA; TRUST/RV368 Study Group.

Ann Epidemiol. 2019 Mar;31:11-19.e3. doi: 10.1016/j.annepidem.2018.12.004. Epub 2018 Dec 21.

PMID:
30642695
18.

Molecular epidemiology of a primarily MSM acute HIV-1 cohort in Bangkok, Thailand and connections within networks of transmission in Asia.

Chang D, Sanders-Buell E, Bose M, O'Sullivan AM, Pham P, Kroon E, Colby DJ, Sirijatuphat R, Billings E, Pinyakorn S, Chomchey N, Rutvisuttinunt W, Kijak G, de Souza M, Excler JL, Phanuphak P, Phanuphak N, O'Connell RJ, Kim JH, Robb ML, Michael NL, Ananworanich J, Tovanabutra S; RV254/SEARCH 010 Study Group.

J Int AIDS Soc. 2018 Nov;21(11):e25204. doi: 10.1002/jia2.25204.

19.

Design and characterization of a self-assembling protein nanoparticle displaying HIV-1 Env V1V2 loop in a native-like trimeric conformation as vaccine antigen.

Karch CP, Bai H, Torres OB, Tucker CA, Michael NL, Matyas GR, Rolland M, Burkhard P, Beck Z.

Nanomedicine. 2019 Feb;16:206-216. doi: 10.1016/j.nano.2018.12.001. Epub 2018 Dec 18.

PMID:
30576800
20.

Prevention of SIVmac251 reservoir seeding in rhesus monkeys by early antiretroviral therapy.

Whitney JB, Lim SY, Osuna CE, Kublin JL, Chen E, Yoon G, Liu PT, Abbink P, Borducci EN, Hill A, Lewis MG, Geleziunas R, Robb ML, Michael NL, Barouch DH.

Nat Commun. 2018 Dec 21;9(1):5429. doi: 10.1038/s41467-018-07881-9.

21.

Individual and Sexual Network Predictors of HIV Incidence Among Men Who Have Sex With Men in Nigeria.

Nowak RG, Mitchell A, Crowell TA, Liu H, Ketende S, Ramadhani HO, Ndembi N, Adebajo S, Ake J, Michael NL, Blattner WA, Baral SD, Charurat ME.

J Acquir Immune Defic Syndr. 2019 Apr 1;80(4):444-453. doi: 10.1097/QAI.0000000000001934.

22.

Noninfectious Comorbidity in the African Cohort Study (AFRICOS).

Ake JA, Polyak CS, Crowell TA, Kiweewa F, Semwogerere M, Maganga L, Bahemana E, Maswai J, Langat R, Owuoth J, Otieno S, Keshinro B, Esber AL, Liu M, Eller LA, Ganesan K, Parikh AP, Hamm TE, Robb ML, Hickey PW, Valcour VG, Michael NL; AFRICOS Study Team.

Clin Infect Dis. 2018 Nov 26. doi: 10.1093/cid/ciy981. [Epub ahead of print]

PMID:
30476001
23.

Full-length next-generation sequencing of HLA class I and II genes in a cohort from Thailand.

Geretz A, Ehrenberg PK, Bouckenooghe A, Fernández Viña MA, Michael NL, Chansinghakule D, Limkittikul K, Thomas R.

Hum Immunol. 2018 Nov;79(11):773-780. doi: 10.1016/j.humimm.2018.09.005. Epub 2018 Sep 19.

PMID:
30243890
24.

Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans.

Pissani F, Schulte B, Eller MA, Schultz BT, Ratto-Kim S, Marovich M, Thongcharoen P, Sriplienchan S, Rerks-Ngarm S, Pitisuttithum P, Esser S, Alter G, Robb ML, Kim JH, Michael NL, Streeck H.

J Virol. 2018 Nov 12;92(23). pii: e01143-18. doi: 10.1128/JVI.01143-18. Print 2018 Dec 1.

25.

Biomarkers of Inflammation Correlate With Clinical Scoring Indices in Human Immunodeficiency Virus-Infected Kenyans.

Letizia A, Eller MA, Polyak C, Eller LA, Creegan M, Dawson P, Bryant C, D K, Crowell TA, Lombardi K, Rono E, Robb ML, Michael NL, Maswai J, Ake JA.

J Infect Dis. 2019 Jan 7;219(2):284-294. doi: 10.1093/infdis/jiy509.

PMID:
30165548
26.

A flow cytometry based assay that simultaneously measures cytotoxicity and monocyte mediated antibody dependent effector activity.

Alrubayyi A, Schuetz A, Lal KG, Jongrakthaitae S, Paolino KM, Ake JA, Robb ML, de Souza MS, Michael NL, Paquin-Proulx D, Eller MA.

J Immunol Methods. 2018 Nov;462:74-82. doi: 10.1016/j.jim.2018.08.012. Epub 2018 Aug 24.

27.

Transmission dynamics among participants initiating antiretroviral therapy upon diagnosis of early acute HIV-1 infection in Thailand.

Kroon E, Pham PT, Sirivichayakul S, Trichavaroj R, Colby DJ, Pinyakorn S, Phanuphak N, Sanders-Buell E, van Griensven F, Kijak GH, Kim JH, Michael NL, Robb ML, Ananworanich J, De Souza MS, Tovanabutra S; RV254/SEARCH 010 Study Group.

AIDS. 2018 Oct 23;32(16):2373-2381. doi: 10.1097/QAD.0000000000001956.

PMID:
30096068
28.

Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).

Barouch DH, Tomaka FL, Wegmann F, Stieh DJ, Alter G, Robb ML, Michael NL, Peter L, Nkolola JP, Borducchi EN, Chandrashekar A, Jetton D, Stephenson KE, Li W, Korber B, Tomaras GD, Montefiori DC, Gray G, Frahm N, McElrath MJ, Baden L, Johnson J, Hutter J, Swann E, Karita E, Kibuuka H, Mpendo J, Garrett N, Mngadi K, Chinyenze K, Priddy F, Lazarus E, Laher F, Nitayapan S, Pitisuttithum P, Bart S, Campbell T, Feldman R, Lucksinger G, Borremans C, Callewaert K, Roten R, Sadoff J, Scheppler L, Weijtens M, Feddes-de Boer K, van Manen D, Vreugdenhil J, Zahn R, Lavreys L, Nijs S, Tolboom J, Hendriks J, Euler Z, Pau MG, Schuitemaker H.

Lancet. 2018 Jul 21;392(10143):232-243. doi: 10.1016/S0140-6736(18)31364-3. Epub 2018 Jul 6.

29.

Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.

Bekker LG, Moodie Z, Grunenberg N, Laher F, Tomaras GD, Cohen KW, Allen M, Malahleha M, Mngadi K, Daniels B, Innes C, Bentley C, Frahm N, Morris DE, Morris L, Mkhize NN, Montefiori DC, Sarzotti-Kelsoe M, Grant S, Yu C, Mehra VL, Pensiero MN, Phogat S, DiazGranados CA, Barnett SW, Kanesa-Thasan N, Koutsoukos M, Michael NL, Robb ML, Kublin JG, Gilbert PB, Corey L, Gray GE, McElrath MJ; HVTN 100 Protocol Team.

Lancet HIV. 2018 Jul;5(7):e366-e378. doi: 10.1016/S2352-3018(18)30071-7. Epub 2018 Jun 18.

30.

Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection.

Colby DJ, Trautmann L, Pinyakorn S, Leyre L, Pagliuzza A, Kroon E, Rolland M, Takata H, Buranapraditkun S, Intasan J, Chomchey N, Muir R, Haddad EK, Tovanabutra S, Ubolyam S, Bolton DL, Fullmer BA, Gorelick RJ, Fox L, Crowell TA, Trichavaroj R, O'Connell R, Chomont N, Kim JH, Michael NL, Robb ML, Phanuphak N, Ananworanich J; RV411 study group.

Nat Med. 2018 Jul;24(7):923-926. doi: 10.1038/s41591-018-0026-6. Epub 2018 Jun 11.

31.

HIV Preexposure Prophylaxis in the U.S. Military Services - 2014-2016.

Blaylock JM, Hakre S, Okulicz JF, Garges E, Wilson K, Lay J, Roska EA, Michael NL, Beckett CG, Cersovsky SB, Peel SA, Scott PT.

MMWR Morb Mortal Wkly Rep. 2018 May 25;67(20):569-574. doi: 10.15585/mmwr.mm6720a1.

32.

Distinct biomarker signatures in HIV acute infection associate with viral dynamics and reservoir size.

Teigler JE, Leyre L, Chomont N, Slike B, Jian N, Eller MA, Phanuphak N, Kroon E, Pinyakorn S, Eller LA, Robb ML, Ananworanich J, Michael NL, Streeck H, Krebs SJ; RV254/RV217 study groups.

JCI Insight. 2018 May 17;3(10). pii: 98420. doi: 10.1172/jci.insight.98420. eCollection 2018 May 17.

33.

Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations.

Akapirat S, Karnasuta C, Vasan S, Rerks-Ngarm S, Pitisuttithum P, Madnote S, Savadsuk H, Rittiroongrad S, Puangkaew J, Phogat S, Tartaglia J, Sinangil F, de Souza MS, Excler JL, Kim JH, Robb ML, Michael NL, Ngauy V, O'Connell RJ, Karasavvas N; RV305 Study Group.

PLoS One. 2018 Apr 27;13(4):e0196397. doi: 10.1371/journal.pone.0196397. eCollection 2018.

34.

Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant.

Wen Y, Trinh HV, Linton CE, Tani C, Norais N, Martinez-Guzman D, Ramesh P, Sun Y, Situ F, Karaca-Griffin S, Hamlin C, Onkar S, Tian S, Hilt S, Malyala P, Lodaya R, Li N, Otten G, Palladino G, Friedrich K, Aggarwal Y, LaBranche C, Duffy R, Shen X, Tomaras GD, Montefiori DC, Fulp W, Gottardo R, Burke B, Ulmer JB, Zolla-Pazner S, Liao HX, Haynes BF, Michael NL, Kim JH, Rao M, O'Connell RJ, Carfi A, Barnett SW.

PLoS One. 2018 Apr 26;13(4):e0194266. doi: 10.1371/journal.pone.0194266. eCollection 2018.

35.

First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector.

Baden LR, Walsh SR, Seaman MS, Cohen YZ, Johnson JA, Licona JH, Filter RD, Kleinjan JA, Gothing JA, Jennings J, Peter L, Nkolola J, Abbink P, Borducchi EN, Kirilova M, Stephenson KE, Pegu P, Eller MA, Trinh HV, Rao M, Ake JA, Sarnecki M, Nijs S, Callewaert K, Schuitemaker H, Hendriks J, Pau MG, Tomaka F, Korber BT, Alter G, Dolin R, Earl PL, Moss B, Michael NL, Robb ML, Barouch DH; IPCAVD006/RV380/HIV-V-A002 Study Group .

J Infect Dis. 2018 Jul 13;218(4):633-644. doi: 10.1093/infdis/jiy212.

36.

Evaluating Vaccination Strategies for Zika Virus in the Americas.

Durham DP, Fitzpatrick MC, Ndeffo-Mbah ML, Parpia AS, Michael NL, Galvani AP.

Ann Intern Med. 2018 May 1;168(9):621-630. doi: 10.7326/M17-0641. Epub 2018 Apr 3.

37.

Identification of Proteins Required for Precise Positioning of Apc2 in Dendrites.

Weiner AT, Seebold DY, Michael NL, Guignet M, Feng C, Follick B, Yusko BA, Wasilko NP, Torres-Gutierrez P, Rolls MM.

G3 (Bethesda). 2018 May 4;8(5):1841-1853. doi: 10.1534/g3.118.200205.

38.

Transcriptomic signatures of NK cells suggest impaired responsiveness in HIV-1 infection and increased activity post-vaccination.

Costanzo MC, Kim D, Creegan M, Lal KG, Ake JA, Currier JR, Streeck H, Robb ML, Michael NL, Bolton DL, Steers NJ, Eller MA.

Nat Commun. 2018 Mar 23;9(1):1212. doi: 10.1038/s41467-018-03618-w.

39.

Central Nervous System Inflammation and Infection during Early, Nonaccelerated Simian-Human Immunodeficiency Virus Infection in Rhesus Macaques.

Hsu DC, Sunyakumthorn P, Wegner M, Schuetz A, Silsorn D, Estes JD, Deleage C, Tomusange K, Lakhashe SK, Ruprecht RM, Lombardini E, Im-Erbsin R, Kuncharin Y, Phuang-Ngern Y, Inthawong D, Chuenarom W, Burke R, Robb ML, Ndhlovu LC, Ananworanich J, Valcour V, O'Connell RJ, Spudich S, Michael NL, Vasan S.

J Virol. 2018 May 14;92(11). pii: e00222-18. doi: 10.1128/JVI.00222-18. Print 2018 Jun 1.

40.

Neutralization Sensitivity of a Novel HIV-1 CRF01_AE Panel of Infectious Molecular Clones.

Chenine AL, Merbah M, Wieczorek L, Molnar S, Mann B, Lee J, OʼSullivan AM, Bose M, Sanders-Buell E, Kijak GH, Herrera C, McLinden R, OʼConnell RJ, Michael NL, Robb ML, Kim JH, Polonis VR, Tovanabutra S.

J Acquir Immune Defic Syndr. 2018 Jul 1;78(3):348-355. doi: 10.1097/QAI.0000000000001675.

41.

HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis.

Wills S, Hwang KK, Liu P, Dennison SM, Tay MZ, Shen X, Pollara J, Lucas JT, Parks R, Rerks-Ngarm S, Pitisuttithum P, Nitayapan S, Kaewkungwal J, Thomas R, Kim JH, Michael NL, Robb ML, McRaven M, Montefiori DC, Hope TJ, Liao HX, Moody MA, Ferrari G, Haynes BF, Alam SM, Bonsignori M, Tomaras GD.

J Virol. 2018 Mar 14;92(7). pii: e01552-17. doi: 10.1128/JVI.01552-17. Print 2018 Apr 1.

42.

Elevated HLA-A expression impairs HIV control through inhibition of NKG2A-expressing cells.

Ramsuran V, Naranbhai V, Horowitz A, Qi Y, Martin MP, Yuki Y, Gao X, Walker-Sperling V, Del Prete GQ, Schneider DK, Lifson JD, Fellay J, Deeks SG, Martin JN, Goedert JJ, Wolinsky SM, Michael NL, Kirk GD, Buchbinder S, Haas D, Ndung'u T, Goulder P, Parham P, Walker BD, Carlson JM, Carrington M.

Science. 2018 Jan 5;359(6371):86-90. doi: 10.1126/science.aam8825. Epub 2018 Jan 4.

43.

Heroin-HIV-1 (H2) vaccine: induction of dual immunologic effects with a heroin hapten-conjugate and an HIV-1 envelope V2 peptide with liposomal lipid A as an adjuvant.

Torres OB, Matyas GR, Rao M, Peachman KK, Jalah R, Beck Z, Michael NL, Rice KC, Jacobson AE, Alving CR.

NPJ Vaccines. 2017 May 2;2:13. doi: 10.1038/s41541-017-0013-9. eCollection 2017.

44.

Durability and correlates of vaccine protection against Zika virus in rhesus monkeys.

Abbink P, Larocca RA, Visitsunthorn K, Boyd M, De La Barrera RA, Gromowski GD, Kirilova M, Peterson R, Li Z, Nanayakkara O, Nityanandam R, Mercado NB, Borducchi EN, Chandrashekar A, Jetton D, Mojta S, Gandhi P, LeSuer J, Khatiwada S, Lewis MG, Modjarrad K, Jarman RG, Eckels KH, Thomas SJ, Michael NL, Barouch DH.

Sci Transl Med. 2017 Dec 13;9(420). pii: eaao4163. doi: 10.1126/scitranslmed.aao4163. Erratum in: Sci Transl Med. 2018 Jul 18;10(450):.

45.

Acute Retroviral Syndrome Is Associated With High Viral Burden, CD4 Depletion, and Immune Activation in Systemic and Tissue Compartments.

Crowell TA, Colby DJ, Pinyakorn S, Fletcher JLK, Kroon E, Schuetz A, Krebs SJ, Slike BM, Leyre L, Chomont N, Jagodzinski LL, Sereti I, Utay NS, Dewar R, Rerknimitr R, Chomchey N, Trichavaroj R, Valcour VG, Spudich S, Michael NL, Robb ML, Phanuphak N, Ananworanich J; RV254/SEARCH010 Study Group .

Clin Infect Dis. 2018 May 2;66(10):1540-1549. doi: 10.1093/cid/cix1063.

46.

Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials.

Modjarrad K, Lin L, George SL, Stephenson KE, Eckels KH, De La Barrera RA, Jarman RG, Sondergaard E, Tennant J, Ansel JL, Mills K, Koren M, Robb ML, Barrett J, Thompson J, Kosel AE, Dawson P, Hale A, Tan CS, Walsh SR, Meyer KE, Brien J, Crowell TA, Blazevic A, Mosby K, Larocca RA, Abbink P, Boyd M, Bricault CA, Seaman MS, Basil A, Walsh M, Tonwe V, Hoft DF, Thomas SJ, Barouch DH, Michael NL.

Lancet. 2018 Feb 10;391(10120):563-571. doi: 10.1016/S0140-6736(17)33106-9. Epub 2017 Dec 5.

47.

Clinical trial design: The nobility of randomization.

Michael NL.

Sci Transl Med. 2017 Dec 6;9(419). pii: eaaq0810. doi: 10.1126/scitranslmed.aaq0810. Review.

PMID:
29212710
48.

Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120.

deCamp AC, Rolland M, Edlefsen PT, Sanders-Buell E, Hall B, Magaret CA, Fiore-Gartland AJ, Juraska M, Carpp LN, Karuna ST, Bose M, LePore S, Miller S, O'Sullivan A, Poltavee K, Bai H, Dommaraju K, Zhao H, Wong K, Chen L, Ahmed H, Goodman D, Tay MZ, Gottardo R, Koup RA, Bailer R, Mascola JR, Graham BS, Roederer M, O'Connell RJ, Michael NL, Robb ML, Adams E, D'Souza P, Kublin J, Corey L, Geraghty DE, Frahm N, Tomaras GD, McElrath MJ, Frenkel L, Styrchak S, Tovanabutra S, Sobieszczyk ME, Hammer SM, Kim JH, Mullins JI, Gilbert PB.

PLoS One. 2017 Nov 17;12(11):e0185959. doi: 10.1371/journal.pone.0185959. eCollection 2017.

49.

Human Primary Macrophages Derived In Vitro from Circulating Monocytes Comprise Adherent and Non-Adherent Subsets with Differential Expression of Siglec-1 and CD4 and Permissiveness to HIV-1 Infection.

Jobe O, Kim J, Tycksen E, Onkar S, Michael NL, Alving CR, Rao M.

Front Immunol. 2017 Oct 23;8:1352. doi: 10.3389/fimmu.2017.01352. eCollection 2017.

50.

Population-based Neisseria gonorrhoeae, Chlamydia trachomatis and Trichomonas vaginalis prevalence using discarded, deidentified urine specimens previously collected for drug testing.

Harbertson J, Jamerson M, Graf PCF, Kennemur L, House B, Michael NL, Scott P, Hale B.

Sex Transm Infect. 2018 Mar;94(2):123. doi: 10.1136/sextrans-2017-053355. Epub 2017 Oct 24. No abstract available.

Supplemental Content

Loading ...
Support Center